Clinical Trials Browser

Lymphoma, B-Cell × loncastuximab tesirine × 1 year × Clear all

NCT04970901 2026-03-13

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

Phase 1 Recruiting

Lymphoma, B-Cell

NCT05453396 2025-10-16

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05270057 2025-10-09

LONCA

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, B-Cell